Resumen

Clinical management of hyperglycemia in patients with type 2 diabetes mellitus is guided not only by published treatment algorithms, but also by consideration of recent evidence and through expert consultation. Recent studies have increased the amount of information regarding the use of glucagon-like peptide-1 receptor agonists. These are a relatively new class of drugs used for management of type 2 diabetes mellitus. They offer a unique and innovative treatment for the management of type 2 diabetes mellitus and demonstrate benefits not only in regard to blood glucose control, but potentially improving other diabetes-related comorbid conditions such as hypertension, hyperlipidemia, and obesity. As the number of glucagon-like peptide-1 receptor agonists continues to become available, physicians will soon face the challenge of selecting the right option for their patients’ needs. These compounds, although all based on the effects of native glucagon-like peptide-1, differ with regard to structure, pharmacokinetics, and size, which ultimately leads to different clinical effects.

Palabras clave: Dulaglutide exenatide exenatide once-weekly GLP-1 receptors agonist liraglutide lixisenatide type 2 diabetes mellitus

2017-05-23   |   261 visitas   |   Evalua este artículo 0 valoraciones

Vol. 3 Núm.3. Julio-Septiembre 2016 Pags. 137-148 Rev Mex Endocrinol Metabol Nut 2016; 3(3)